The car-t therapy market size has grown rapidly in recent years. It will grow from $2.98 billion in 2025 to $3.45 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to limited availability of personalized immunotherapy, high cost of early car-t treatments, dependence on hospital-based cell processing, nascent regulatory frameworks, low patient awareness of car-t therapy.
The car-t therapy market size is expected to see rapid growth in the next few years. It will grow to $6.08 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to technological advancements in t-cell engineering, growing investment in oncology research, expansion of commercial car-t manufacturing facilities, increasing regulatory approvals, rising collaborations between biopharma and academic institutions. Major trends in the forecast period include rising adoption of car-t therapies in hematologic malignancies, development of targeted antigen-specific car-t treatments, increasing use of combination therapy approaches, expansion of clinical trials and research programs, focus on reducing therapy costs and enhancing accessibility.
The rising prevalence of cancer is anticipated to support the expansion of the CAR-T therapy market going forward. The increasing prevalence of cancer refers to the growing number of diagnosed cancer cases within a population over time. This trend has accelerated research efforts and investment in advanced cancer treatments, including cellular immunotherapies, which represent a major advancement in oncology. These therapies are particularly relevant for addressing unmet needs among cancer patients. For example, in July 2024, according to the Australian Institute of Health and Welfare, a government agency in Australia, cancer diagnoses increased from 160,570 in 2022 to 164,694 in 2023, highlighting a continued upward trend nationwide. As a result, the rising prevalence of cancer is contributing to the expansion of the CAR-T therapy market.
Leading companies operating in the CAR-T therapy market are focusing on developing technologically advanced solutions, such as diagnostic tools, to support treatment personalization and improve patient outcomes. Diagnostic tools include instruments, devices, and software used to identify diseases, assess health conditions, and guide treatment planning. For example, in February 2023, Eurofins Viracor, a US-based clinical diagnostic laboratory, launched the ExPeCT Expansion and Persistence of CAR T Assay. This assay enables longitudinal monitoring of CAR T-cell expansion and persistence, providing real-time data to assess therapy effectiveness. It also helps identify patients at risk of treatment failure due to insufficient CAR T-cell dynamics, allowing earlier clinical intervention and improved outcomes in hematological malignancies.
In July 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired Iveric Bio for $5.9 billion. With this acquisition, Astellas is better positioned to support patients with ocular diseases at high risk of vision loss. The combination of Iveric Bio’s ophthalmology expertise and Astellas’ global resources presents an opportunity to advance treatments for blinding retinal conditions, including geographic atrophy (GA). The transaction was subject to approval by Iveric Bio’s shareholders and other customary closing conditions, including regulatory approvals. Iveric Bio is a US-based biotechnology company.
Major companies operating in the car-t therapy market are Gilead Sciences, Novartis AG, Biocon, Gracell Biotechnology Ltd., CARsgen Therapeutics, Takeda Pharmaceutical Company, Astellas Pharma, Innovative Cellular Therapeutics, Cellular Biomedicine Group, PersonGen Biomedicine, Hebei Senlang Biotech, Adaptimmune (UK), Autolus Therapeutics, BioNTech, Cellectis, Celyad, Immatics, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen, AstraZeneca, Merck, Pfizer, Juno Therapeutics, Allogene Therapeutics, Precision BioSciences, Bellicum, GlaxoSmithKline plc.
North America was the largest region in the CAR-T therapy market in 2025. Western Europe was the second-largest region in the global CAR-T therapy market share. The regions covered in the car-t therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the car-t therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the CAR-T therapy market by increasing costs for imported laboratory equipment, cell culture media, and reagents required for manufacturing CAR-T cells. Segments like CD19-targeted and BCMA-targeted therapies are particularly affected, with regions such as North America and Europe facing supply chain challenges due to import duties. While tariffs create higher operational costs and potential delays, they also encourage localized production of reagents and equipment, which can strengthen domestic manufacturing capabilities and reduce long-term dependence on imports.
The car-t therapy market research report is one of a series of new reports that provides car-t therapy market statistics, including car-t therapy industry global market size, regional shares, competitors with a car-t therapy market share, detailed car-t therapy market segments, market trends and opportunities, and any further data you may need to thrive in the car-t therapy industry. This car-t therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Chimeric antigen receptor (CAR) T-cell therapy is a form of immunotherapy in which T-cells are taken from a patient’s blood, modified in a laboratory to express a special receptor that recognizes and destroys cancer cells, and then infused back into the patient. These engineered T-cells multiply and persist in the body as living drugs, targeting cancer cells more effectively.
The primary types of chimeric antigen receptor T-cell therapy include monotherapy and combination therapy. Monotherapy involves the use of a single drug for the treatment of a disease. The target antigens include CD19, CD22, and others, and the applications cover acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and others.
The chimeric antigen receptor -T therapy market includes revenues earned by CAR-T therapy products and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The car-t therapy market size is expected to see rapid growth in the next few years. It will grow to $6.08 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to technological advancements in t-cell engineering, growing investment in oncology research, expansion of commercial car-t manufacturing facilities, increasing regulatory approvals, rising collaborations between biopharma and academic institutions. Major trends in the forecast period include rising adoption of car-t therapies in hematologic malignancies, development of targeted antigen-specific car-t treatments, increasing use of combination therapy approaches, expansion of clinical trials and research programs, focus on reducing therapy costs and enhancing accessibility.
The rising prevalence of cancer is anticipated to support the expansion of the CAR-T therapy market going forward. The increasing prevalence of cancer refers to the growing number of diagnosed cancer cases within a population over time. This trend has accelerated research efforts and investment in advanced cancer treatments, including cellular immunotherapies, which represent a major advancement in oncology. These therapies are particularly relevant for addressing unmet needs among cancer patients. For example, in July 2024, according to the Australian Institute of Health and Welfare, a government agency in Australia, cancer diagnoses increased from 160,570 in 2022 to 164,694 in 2023, highlighting a continued upward trend nationwide. As a result, the rising prevalence of cancer is contributing to the expansion of the CAR-T therapy market.
Leading companies operating in the CAR-T therapy market are focusing on developing technologically advanced solutions, such as diagnostic tools, to support treatment personalization and improve patient outcomes. Diagnostic tools include instruments, devices, and software used to identify diseases, assess health conditions, and guide treatment planning. For example, in February 2023, Eurofins Viracor, a US-based clinical diagnostic laboratory, launched the ExPeCT Expansion and Persistence of CAR T Assay. This assay enables longitudinal monitoring of CAR T-cell expansion and persistence, providing real-time data to assess therapy effectiveness. It also helps identify patients at risk of treatment failure due to insufficient CAR T-cell dynamics, allowing earlier clinical intervention and improved outcomes in hematological malignancies.
In July 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired Iveric Bio for $5.9 billion. With this acquisition, Astellas is better positioned to support patients with ocular diseases at high risk of vision loss. The combination of Iveric Bio’s ophthalmology expertise and Astellas’ global resources presents an opportunity to advance treatments for blinding retinal conditions, including geographic atrophy (GA). The transaction was subject to approval by Iveric Bio’s shareholders and other customary closing conditions, including regulatory approvals. Iveric Bio is a US-based biotechnology company.
Major companies operating in the car-t therapy market are Gilead Sciences, Novartis AG, Biocon, Gracell Biotechnology Ltd., CARsgen Therapeutics, Takeda Pharmaceutical Company, Astellas Pharma, Innovative Cellular Therapeutics, Cellular Biomedicine Group, PersonGen Biomedicine, Hebei Senlang Biotech, Adaptimmune (UK), Autolus Therapeutics, BioNTech, Cellectis, Celyad, Immatics, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen, AstraZeneca, Merck, Pfizer, Juno Therapeutics, Allogene Therapeutics, Precision BioSciences, Bellicum, GlaxoSmithKline plc.
North America was the largest region in the CAR-T therapy market in 2025. Western Europe was the second-largest region in the global CAR-T therapy market share. The regions covered in the car-t therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the car-t therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the CAR-T therapy market by increasing costs for imported laboratory equipment, cell culture media, and reagents required for manufacturing CAR-T cells. Segments like CD19-targeted and BCMA-targeted therapies are particularly affected, with regions such as North America and Europe facing supply chain challenges due to import duties. While tariffs create higher operational costs and potential delays, they also encourage localized production of reagents and equipment, which can strengthen domestic manufacturing capabilities and reduce long-term dependence on imports.
The car-t therapy market research report is one of a series of new reports that provides car-t therapy market statistics, including car-t therapy industry global market size, regional shares, competitors with a car-t therapy market share, detailed car-t therapy market segments, market trends and opportunities, and any further data you may need to thrive in the car-t therapy industry. This car-t therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Chimeric antigen receptor (CAR) T-cell therapy is a form of immunotherapy in which T-cells are taken from a patient’s blood, modified in a laboratory to express a special receptor that recognizes and destroys cancer cells, and then infused back into the patient. These engineered T-cells multiply and persist in the body as living drugs, targeting cancer cells more effectively.
The primary types of chimeric antigen receptor T-cell therapy include monotherapy and combination therapy. Monotherapy involves the use of a single drug for the treatment of a disease. The target antigens include CD19, CD22, and others, and the applications cover acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and others.
The chimeric antigen receptor -T therapy market includes revenues earned by CAR-T therapy products and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. CAR-T Therapy Market Characteristics
3. CAR-T Therapy Market Supply Chain Analysis
4. Global CAR-T Therapy Market Trends and Strategies
5. CAR-T Therapy Market Analysis of End Use Industries
7. Global CAR-T Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global CAR-T Therapy Total Addressable Market (TAM) Analysis for the Market
9. CAR-T Therapy Market Segmentation
10. CAR-T Therapy Market Regional and Country Analysis
11. Asia-Pacific CAR-T Therapy Market
12. China CAR-T Therapy Market
13. India CAR-T Therapy Market
14. Japan CAR-T Therapy Market
15. Australia CAR-T Therapy Market
16. Indonesia CAR-T Therapy Market
17. South Korea CAR-T Therapy Market
18. Taiwan CAR-T Therapy Market
19. South East Asia CAR-T Therapy Market
20. Western Europe CAR-T Therapy Market
21. UK CAR-T Therapy Market
22. Germany CAR-T Therapy Market
23. France CAR-T Therapy Market
24. Italy CAR-T Therapy Market
25. Spain CAR-T Therapy Market
26. Eastern Europe CAR-T Therapy Market
27. Russia CAR-T Therapy Market
28. North America CAR-T Therapy Market
29. USA CAR-T Therapy Market
30. Canada CAR-T Therapy Market
31. South America CAR-T Therapy Market
32. Brazil CAR-T Therapy Market
33. Middle East CAR-T Therapy Market
34. Africa CAR-T Therapy Market
36. CAR-T Therapy Market Competitive Landscape and Company Profiles
37. CAR-T Therapy Market Other Major and Innovative Companies
40. CAR-T Therapy Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
CAR-T Therapy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses car-t therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for car-t therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The car-t therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Monotherapy; Combination Therapy2) By Target Antigen: CD19; CD22; BCMA; Other Target Antigens
3) By Application: Acute Lymphoblastic Leukemia; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Chronic Lymphocytic Leukemia; Multiple Myeloma; Other Applications
Subsegments:
1) By Monotherapy: CD19-targeted CAR-T Therapy; BCMA-Targeted CAR-T Therapy2) By Combination Therapy: CAR-T Therapy With Immune Checkpoint Inhibitors; CAR-T Therapy With Other Targeted Therapies; CAR-T Therapy With Chemotherapy Or Radiotherapy
Companies Mentioned: Gilead Sciences; Novartis AG; Biocon; Gracell Biotechnology Ltd.; CARsgen Therapeutics; Takeda Pharmaceutical Company; Astellas Pharma; Innovative Cellular Therapeutics; Cellular Biomedicine Group; PersonGen Biomedicine; Hebei Senlang Biotech; Adaptimmune (UK); Autolus Therapeutics; BioNTech; Cellectis; Celyad; Immatics; Biocad; Celgene Corporation; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Amgen; AstraZeneca; Merck; Pfizer; Juno Therapeutics; Allogene Therapeutics; Precision BioSciences; Bellicum; GlaxoSmithKline plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this CAR-T Therapy market report include:- Gilead Sciences
- Novartis AG
- Biocon
- Gracell Biotechnology Ltd.
- CARsgen Therapeutics
- Takeda Pharmaceutical Company
- Astellas Pharma
- Innovative Cellular Therapeutics
- Cellular Biomedicine Group
- PersonGen Biomedicine
- Hebei Senlang Biotech
- Adaptimmune (UK)
- Autolus Therapeutics
- BioNTech
- Cellectis
- Celyad
- Immatics
- Biocad
- Celgene Corporation
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Eli Lilly and Company
- Amgen
- AstraZeneca
- Merck
- Pfizer
- Juno Therapeutics
- Allogene Therapeutics
- Precision BioSciences
- Bellicum
- GlaxoSmithKline plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.45 Billion |
| Forecasted Market Value ( USD | $ 6.08 Billion |
| Compound Annual Growth Rate | 15.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 32 |
